Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02481154 · ClinicalTrials.gov registry record · Phase 1
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
A Phase 1 study of Glioma, sponsored by Institut de Recherches Internationales Servier.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 9
- Study locations
NCT02481154 is a Phase 1 study of Glioma that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 95 participants, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (55% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT02481154, a Phase 1 study of Glioma, has completed, sponsored by Institut de Recherches Internationales Servier.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation.
Conditions Studied
Interventions
- DRUG AG881
Study Locations (9)
California
- UCLA Oncology Center - Los Angeles
- University of California San Francisco - San Francisco
Texas
- UT Southwestern Medical Center - Dallas
- MD Anderson Cancer Center - Houston
Florida
- University of Miami - Miami
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University Medical Center - Durham
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2015-06 |
| Est. Completion | 2024-06-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02481154
The ClinicalTrials.gov registry entry for NCT02481154 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 209-participant average among 87 other Glioma trials with a reported enrollment target (55% lower). The listed sponsor is Institut de Recherches Internationales Servier, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which AG881 is the first listed.
NCT02481154 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT02481154 about?
NCT02481154 is a clinical study titled "Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation". This study evaluates the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-881 in Gliomas, that harbor an IDH1 and/or IDH2 mutation.
What is the current status of trial NCT02481154?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2015-06. Estimated completion is 2024-06-19.
What conditions does trial NCT02481154 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT02481154?
The interventions under investigation include: AG881 (DRUG).
Who is sponsoring clinical trial NCT02481154?
This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02481154 being conducted?
This trial has 9 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
A Study of 177Lu-PSMA-617 in People With Gliomas
RECRUITING · Phase 1
-
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.